Thymosin Alpha-1

Thymalfasin (Thymosin Alpha-1)

Evidence & Status

  • Moderate Evidence
  • Moderate

At a Glance

A naturally occurring thymic peptide involved in T-cell maturation and immune system regulation. Used clinically in some countries for chronic viral hepatitis and immune support in cancer patients; studied internationally for its immunomodulatory effects in immune-compromised states.

Plain English

Researchers study Thymosin Alpha-1 because it is a naturally produced signal from the thymus — the gland responsible for educating immune cells — that appears to enhance T-cell maturation and immune responsiveness. Scientists are interested in its potential to support immune function in people with compromised immunity, such as those with chronic viral infections or those undergoing cancer treatment. It is approved for clinical use in several countries and has a meaningful body of human trial data, though it has not received FDA approval.

Overview

Thymosin alpha-1 is a 28-residue immunomodulatory peptide; thymalfasin is the generic substance name and Zadaxin is a product name. It has been studied in chronic hepatitis B and other immune-modulation settings. Human chronic-hepatitis-B evidence is mixed and indication-specific, including favorable findings in some studies and a phase III placebo-controlled study that did not confirm earlier efficacy observations. Product authorization is jurisdiction- and label-specific.

Research Summary

Thymosin alpha-1 has been studied as an immunomodulatory peptide in chronic hepatitis B and other settings. In chronic hepatitis B, the evidence is mixed: the Japanese randomized study reported dose-specific clinical findings, while the multicenter phase III placebo-controlled study did not confirm earlier efficacy observations. A meta-analysis comparing thymosin alpha-1 with interferon-alpha found results that varied by endpoint, timing, and patient subgroup. These findings support an indication-specific evidence summary rather than a uniform efficacy claim. Zadaxin is a product name, and regulatory status must be stated only for a verified jurisdiction and label.

Research Areas

  • Immune enhancement & reconstitution
  • Viral hepatitis (B & C)
  • Cancer immunotherapy
  • COVID-19 critical illness
  • Vaccine adjuvant

Safety & Risks

Serious Risks

  • Theoretical: excessive immune activation in autoimmune conditions; use caution in active autoimmune disease; not FDA-approved

Reported Side Effects

  • Generally very well-tolerated
  • Mild injection site discomfort
  • Low-grade fever (first dose, rare)
United States
Not FDA-approved in the United States.
United Kingdom
Research only
Australia
Research only
Canada
Research only

Citations & Sources